Arvinas Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $25.67
- Today's High:
- $27.81
- Open Price:
- $27.81
- 52W Low:
- $21.21
- 52W High:
- $58.58
- Prev. Close:
- $27.86
- Volume:
- 275342
Company Statistics
- Market Cap.:
- $1.24 billion
- Book Value:
- 9.569
- Revenue TTM:
- $137.40 million
- Operating Margin TTM:
- -213.39%
- Gross Profit TTM:
- $131.40 million
- Profit Margin:
- -219.07%
- Return on Assets TTM:
- -13.76%
- Return on Equity TTM:
- -48.77%
Company Profile
Arvinas Inc had its IPO on 2018-09-27 under the ticker symbol ARVN.
The company operates in the Healthcare sector and Biotechnology industry. Arvinas Inc has a staff strength of 415 employees.
Stock update
Shares of Arvinas Inc opened at $27.81 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $25.67 - $27.81, and closed at $26.36.
This is a -5.38% slip from the previous day's closing price.
A total volume of 275,342 shares were traded at the close of the day’s session.
In the last one week, shares of Arvinas Inc have slipped by -5.35%.
Arvinas Inc's Key Ratios
Arvinas Inc has a market cap of $1.24 billion, indicating a price to book ratio of 3.1294 and a price to sales ratio of 17.6396.
In the last 12-months Arvinas Inc’s revenue was $137.40 million with a gross profit of $131.40 million and an EBITDA of $-287200000. The EBITDA ratio measures Arvinas Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Arvinas Inc’s operating margin was -213.39% while its return on assets stood at -13.76% with a return of equity of -48.77%.
In Q1, Arvinas Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 22.6%.
Arvinas Inc’s PE and PEG Ratio
- Forward PE
- 17.6991
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-5.99 per share while it has a forward price to earnings multiple of 17.6991 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arvinas Inc’s profitability.
Arvinas Inc stock is trading at a EV to sales ratio of 6.0672 and a EV to EBITDA ratio of -2.8613. Its price to sales ratio in the trailing 12-months stood at 17.6396.
Arvinas Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.18 billion
- Total Liabilities
- $282.90 million
- Operating Cash Flow
- $138.60 million
- Capital Expenditure
- $1.10 million
- Dividend Payout Ratio
- 0%
Arvinas Inc ended 2024 with $1.18 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.18 billion while shareholder equity stood at $511.00 million.
Arvinas Inc ended 2024 with $0 in deferred long-term liabilities, $282.90 million in other current liabilities, 100000.00 in common stock, $-1047300000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $130.20 million and cash and short-term investments were $1.12 billion. The company’s total short-term debt was $2,000,000 while long-term debt stood at $900000.00.
Arvinas Inc’s total current assets stands at $1.15 billion while long-term investments were $0 and short-term investments were $993.30 million. Its net receivables were $4.70 million compared to accounts payable of $12.30 million and inventory worth $0.
In 2024, Arvinas Inc's operating cash flow was $138.60 million while its capital expenditure stood at $1.10 million.
Comparatively, Arvinas Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $26.36
- 52-Week High
- $58.58
- 52-Week Low
- $21.21
- Analyst Target Price
- $71.1
Arvinas Inc stock is currently trading at $26.36 per share. It touched a 52-week high of $58.58 and a 52-week low of $58.58. Analysts tracking the stock have a 12-month average target price of $71.1.
Its 50-day moving average was $24.97 and 200-day moving average was $28.78 The short ratio stood at 8.54 indicating a short percent outstanding of 0%.
Around 952.3% of the company’s stock are held by insiders while 9650.5% are held by institutions.
Frequently Asked Questions About Arvinas Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.